CANCER THERAPY

Molecular profiling in precision medicine oncology

Three innovative precision medicine studies show the utility of evidence beyond that from tumor DNA sequencing to guide therapy in patients with cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: New concepts evaluated in the I-PREDICT, TARGET and WINTHER studies.

References

  1. 1.

    Yates, L. R. Ann. Oncol. 29, 30–35 (2018).

  2. 2.

    Le, D. T. New Engl. J. Med. 372, 2509–2520 (2015).

  3. 3.

    Drilon, A. New Engl. J. Med. 378, 731–739 (2018).

  4. 4.

    Rothwell, D. G. Nat. Med. https://doi.org/10.1038/s41591-019-0380-z (2019).

  5. 5.

    Sicklick, J. K. Nat. Med. https://doi.org/10.1038/s41591-019-0407-5 (2019).

  6. 6.

    Rodon, J. Nat. Med. https://doi.org/10.1038/s41591-019-0424-4 (2019).

  7. 7.

    von Hoff, D. D. J. Clin. Oncol. 28, 4877–4883 (2010).

  8. 8.

    Stockley, T. L. Genome Med. 8, 109 (2016).

  9. 9.

    Le Tourneau, C. Lancet Oncol. 16, 1324–1334 (2015).

  10. 10.

    Belin, L. Ann. Oncol. 28, 590–596 (2017).

  11. 11.

    Massard, C. Cancer Disco. 7, 586–595 (2017).

Download references

Author information

All authors contributed to the writing of the manuscript.

Correspondence to Christophe Le Tourneau.

Ethics declarations

Competing interests

C.L.T. has received consultant fees from Merck Serono, Merck & Co., Bristol-Myers Squibb, Amgen, Novartis, GlaxoSmithKline and Roche.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Le Tourneau, C., Borcoman, E. & Kamal, M. Molecular profiling in precision medicine oncology. Nat Med 25, 711–712 (2019). https://doi.org/10.1038/s41591-019-0442-2

Download citation

Further reading